BioCryst Pharmaceuticals Stock Price, News & Analysis (NASDAQ:BCRX)

$4.96 +0.09 (+1.85 %)
(As of 02/20/2018 10:24 AM ET)
Previous Close$4.96
Today's Range$4.88 - $5.24
52-Week Range$3.95 - $9.25
Volume1.53 million shs
Average Volume1.45 million shs
Market Capitalization$488.09 million
P/E Ratio-7.88
Dividend YieldN/A
Beta2.8

About BioCryst Pharmaceuticals (NASDAQ:BCRX)

BioCryst Pharmaceuticals logoBioCryst Pharmaceuticals, Inc. is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases. It uses X-ray crystallography, computer modeling of molecular structures and chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology. The Company's drug candidates include RAPIVAB, RAPIACTA, ALPIVAB, PERAMIFLU, Avoralstat, BCX7353, other second generation hereditary angioedema (HAE) compounds, Galidesivir and Forodesine. Its product RAPIVAB contains peramivir. ALPIVAB is an intravenous neuraminidase inhibitor. Galidesivir is a broad-spectrum antiviral (BSAV) research program developed for the treatment of hemorrhagic fever viruses. Forodesine is a Purine Nucleoside Phosphorylase (PNP) inhibitor in development by Mundipharma as a treatment for cancer.

Receive BCRX News and Ratings via Email

Sign-up to receive the latest news and ratings for BCRX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryBiotechnology
SectorHealthcare
SymbolNASDAQ:BCRX
CUSIP09058V10
Phone+1-919-8591302

Debt

Debt-to-Equity Ratio0.21%
Current Ratio2.53%
Quick Ratio2.53%

Price-To-Earnings

Trailing P/E Ratio-7.8828125
Forward P/E Ratio-7.09
P/E GrowthN/A

Sales & Book Value

Annual Sales$26.35 million
Price / Sales18.53
Cash FlowN/A
Price / CashN/A
Book Value$0.02 per share
Price / Book248.00

Profitability

Trailing EPS($0.64)
Net Income$-55,140,000.00
Net Margins-167.58%
Return on Equity-123.16%
Return on Assets-38.71%

Miscellaneous

Employees65
Outstanding Shares98,430,000

BioCryst Pharmaceuticals (NASDAQ:BCRX) Frequently Asked Questions

What is BioCryst Pharmaceuticals' stock symbol?

BioCryst Pharmaceuticals trades on the NASDAQ under the ticker symbol "BCRX."

How were BioCryst Pharmaceuticals' earnings last quarter?

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) released its quarterly earnings data on Tuesday, November, 7th. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.18). The biotechnology company earned $8.76 million during the quarter, compared to analyst estimates of $5.05 million. BioCryst Pharmaceuticals had a negative net margin of 167.58% and a negative return on equity of 123.16%. The business's quarterly revenue was up 12.9% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.16) earnings per share. View BioCryst Pharmaceuticals' Earnings History.

When will BioCryst Pharmaceuticals make its next earnings announcement?

BioCryst Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, February, 26th 2018. View Earnings Estimates for BioCryst Pharmaceuticals.

Where is BioCryst Pharmaceuticals' stock going? Where will BioCryst Pharmaceuticals' stock price be in 2018?

8 brokerages have issued 12 month target prices for BioCryst Pharmaceuticals' stock. Their predictions range from $6.00 to $15.00. On average, they expect BioCryst Pharmaceuticals' share price to reach $8.83 in the next year. View Analyst Ratings for BioCryst Pharmaceuticals.

What are Wall Street analysts saying about BioCryst Pharmaceuticals stock?

Here are some recent quotes from research analysts about BioCryst Pharmaceuticals stock:

  • 1. HC Wainwright analysts commented, "NewCo Combines HAE Commercial & Deal-Making Expertise With Core Competency in Structure-Based Drug Design Diversification and management expertise drive the deal. Biocryst today announced its intention to merge with the oligomer company Idera (IDRA; Buy Rated) to form a NewCo that will continue to develop treatments for both HAE as well as checkpoint-refractory myeloma." (1/23/2018)
  • 2. According to Zacks Investment Research, "BioCryst Pharmaceuticals, Inc. is a leader in the use of crystallography and structure-based drug design for the development of novel therapeutics to treat cancer, cardiovascular diseases, autoimmune diseases, and viral infections. The company is advancing multiple internal programs toward potential commercialization including Fodosine in oncology, BCX-4208 in transplantation and autoimmune diseases and peramivir in seasonal and life threatening influenza. BioCryst has a worldwide partnership with Roche for the development and commercialization BCX-4208, and is collaborating with Mundipharma for the development and commercialization of Fodosine in markets across Europe, Asia, Australia and certain neighboring countries. " (8/10/2017)
  • 3. Needham & Company LLC analysts commented, "Shire (SHPG) reported positive results from the ph 3 HELP trial evaluating lanadelumab (fka SHP643) as a prophylactic HAE treatment. Lanadelumab, an antibody that binds and inhibits plasma kallikrein, is formulated for subcutaneous administration and has a long half-life (~14 days) that enables once- or twice-monthly dosing. The HELP trial met all of its endpoints; monthly attack rate reduction vs. placebo for all dosing regimens ranged from 73% – 87% (p<0.001). A BLA filing for lanadelumab is expected in late-2017/early-2018. BCRX's BCX7353, a daily orally-administered HAE prophylactic candidate, is currently under evaluation in the ph 2 APeX-1 trial. Positive interim results reported in late-Feb showed that BCX7353 led to a ~52% HAE attack rate reduction (p=0.035, ITT), with results showing a dichotomy of efficacy between peripheral attacks (~88% reduction) and abdominal attacks (~24% reduction). Additional APeX-1 cohorts evaluating lower-doses of BCX7353 are expected to report in 2Q17. These data should provide clarity on the efficacy/tolerability profile of BCX7353 and help shed some light on its potential role in HAE prophylaxis."" (5/19/2017)

Who are some of BioCryst Pharmaceuticals' key competitors?

Who are BioCryst Pharmaceuticals' key executives?

BioCryst Pharmaceuticals' management team includes the folowing people:

  • Robert A. Ingram, Chairman of the Board (Age 74)
  • Jon P. Stonehouse, President, Chief Executive Officer, Director (Age 56)
  • Thomas R. Staab II, Chief Financial Officer, Senior Vice President, Principal Accounting Officer, Treasurer (Age 52)
  • Yarlagadda S. Babu Ph.D., Senior Vice President - Drug Discovery (Age 64)
  • Lynne M. Powell, Senior Vice President, Chief Commercial Officer (Age 50)
  • William P. Sheridan, Senior Vice President, Chief Medical Officer (Age 62)
  • Alane P. Barnes, Vice President, General Counsel, and Corporate Secretary (Age 51)
  • Fred E. Cohen Ph.D. M.D., Director (Age 60)
  • Sanj K. Patel, Director (Age 46)
  • George B. Abercrombie, Independent Director (Age 62)

Who owns BioCryst Pharmaceuticals stock?

BioCryst Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional investors include BlackRock Inc. (7.74%), GREAT POINT PARTNERS LLC (7.60%), GREAT POINT PARTNERS LLC (7.60%), Millennium Management LLC (3.77%), RTW Investments LP (3.43%) and VHCP Management II LLC (2.52%). Company insiders that own BioCryst Pharmaceuticals stock include Alane P Barnes, Bros Advisors Lp Baker, Fred E Cohen, Thomas R Staab II, William P Sheridan and Yarlagadda S Babu. View Institutional Ownership Trends for BioCryst Pharmaceuticals.

Who sold BioCryst Pharmaceuticals stock? Who is selling BioCryst Pharmaceuticals stock?

BioCryst Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including VHCP Management II LLC, Artal Group S.A., Millennium Management LLC, Wells Fargo & Company MN, Metropolitan Life Insurance Co. NY and Rhumbline Advisers. Company insiders that have sold BioCryst Pharmaceuticals company stock in the last year include Fred E Cohen, Thomas R Staab II and William P Sheridan. View Insider Buying and Selling for BioCryst Pharmaceuticals.

Who bought BioCryst Pharmaceuticals stock? Who is buying BioCryst Pharmaceuticals stock?

BioCryst Pharmaceuticals' stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Rock Springs Capital Management LP, Deutsche Bank AG, Eversept Partners LLC, Two Sigma Investments LP, Schwab Charles Investment Management Inc., Renaissance Technologies LLC and Tekla Capital Management LLC. View Insider Buying and Selling for BioCryst Pharmaceuticals.

How do I buy BioCryst Pharmaceuticals stock?

Shares of BioCryst Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is BioCryst Pharmaceuticals' stock price today?

One share of BioCryst Pharmaceuticals stock can currently be purchased for approximately $4.96.

How big of a company is BioCryst Pharmaceuticals?

BioCryst Pharmaceuticals has a market capitalization of $488.09 million and generates $26.35 million in revenue each year. The biotechnology company earns $-55,140,000.00 in net income (profit) each year or ($0.64) on an earnings per share basis. BioCryst Pharmaceuticals employs 65 workers across the globe.

How can I contact BioCryst Pharmaceuticals?

BioCryst Pharmaceuticals' mailing address is 4505 Emperor Blvd Ste 200, DURHAM, NC 27703-8457, United States. The biotechnology company can be reached via phone at +1-919-8591302 or via email at [email protected]


MarketBeat Community Rating for BioCryst Pharmaceuticals (BCRX)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  272 (Vote Outperform)
Underperform Votes:  246 (Vote Underperform)
Total Votes:  518
MarketBeat's community ratings are surveys of what our community members think about BioCryst Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

BioCryst Pharmaceuticals (NASDAQ:BCRX) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.632.702.702.88
Ratings Breakdown: 0 Sell Rating(s)
3 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
3 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
3 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $8.83$9.14$9.71$8.50
Price Target Upside: 66.04% upside86.21% upside106.69% upside89.10% upside

BioCryst Pharmaceuticals (NASDAQ:BCRX) Consensus Price Target History

Price Target History for BioCryst Pharmaceuticals (NASDAQ:BCRX)

BioCryst Pharmaceuticals (NASDAQ:BCRX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/23/2018HC WainwrightReiterated RatingBuy$10.00MediumView Rating Details
1/2/2018Royal Bank of CanadaUpgradeSector Perform -> Outperform$6.00HighView Rating Details
12/20/2017BarclaysInitiated CoverageEqual Weight -> Equal Weight$6.00MediumView Rating Details
9/6/2017JPMorgan Chase & Co.Boost Price TargetOverweight -> Neutral$4.93 -> $9.00HighView Rating Details
9/6/2017Jefferies GroupUpgradeHold -> Buy$5.00 -> $7.00HighView Rating Details
9/5/2017Piper Jaffray CompaniesReiterated RatingOverweight$13.00 -> $15.00HighView Rating Details
8/8/2017Noble FinancialReiterated RatingBuyLowView Rating Details
5/19/2017Needham & Company LLCReiterated RatingHoldMediumView Rating Details
2/16/2017Ladenburg Thalmann Financial ServicesInitiated CoverageBuy$11.00N/AView Rating Details
1/23/2017FBR & CoReiterated RatingOutperformN/AView Rating Details
12/16/2016JMP SecuritiesUpgradeMarket Perform -> Outperform$10.00N/AView Rating Details
(Data available from 2/20/2016 forward)

Earnings

BioCryst Pharmaceuticals (NASDAQ:BCRX) Earnings History and Estimates Chart

Earnings by Quarter for BioCryst Pharmaceuticals (NASDAQ:BCRX)

BioCryst Pharmaceuticals (NASDAQ BCRX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/26/2018($0.15)N/AView Earnings Details
11/7/2017Q3 2017($0.18)($0.18)$5.05 million$8.76 millionViewN/AView Earnings Details
8/7/2017Q2 2017($0.19)($0.21)$5.79 million$3.10 millionViewListenView Earnings Details
5/4/2017Q1 2017($0.20)($0.19)$6.13 million$9.40 millionViewListenView Earnings Details
2/27/2017Q416($0.23)($0.06)$4.13 million$9.00 millionViewListenView Earnings Details
11/7/2016Q316($0.24)($0.16)$5.94 million$7.80 millionViewListenView Earnings Details
8/4/2016Q216($0.26)($0.22)$3.92 million$4.80 millionViewN/AView Earnings Details
5/5/2016Q116($0.23)($0.31)$5.42 million$4.82 millionViewN/AView Earnings Details
2/23/2016Q415($0.26)($0.25)$6.34 million$4.60 millionViewListenView Earnings Details
11/5/2015Q315($0.20)($0.20)$6.77 million$11.00 millionViewListenView Earnings Details
8/7/2015Q215($0.22)$0.06$7.10 million$25.80 millionViewListenView Earnings Details
5/8/2015Q115($0.24)($0.21)$4.30 million$6.80 millionViewListenView Earnings Details
2/18/2015Q414($0.20)($0.16)$3.64 million$5.40 millionViewListenView Earnings Details
11/6/2014Q314($0.20)($0.12)$2.11 million$3.20 millionViewListenView Earnings Details
8/5/2014Q214($0.19)($0.23)$2.32 million$1.50 millionViewN/AView Earnings Details
5/8/2014Q114($0.16)($0.17)$3.34 million$3.50 millionViewN/AView Earnings Details
2/26/2014Q413($0.08)($0.09)$8.81 million$10.60 millionViewN/AView Earnings Details
11/5/2013Q313($0.14)($0.14)$2.01 million$2.40 millionViewN/AView Earnings Details
8/8/2013Q2 2013($0.14)($0.23)$2.01 million$0.82 millionViewN/AView Earnings Details
5/7/2013Q1 2013($0.15)($0.09)$1.31 million$3.60 millionViewN/AView Earnings Details
2/19/2013Q4 2012($0.16)($0.22)$4.02 million$4.10 millionViewN/AView Earnings Details
11/8/2012Q312($0.22)($0.19)$4.63 million$5.80 millionViewN/AView Earnings Details
8/2/2012($0.26)($0.25)ViewN/AView Earnings Details
5/7/2012($0.26)($0.13)ViewN/AView Earnings Details
2/16/2012($0.33)($0.29)ViewN/AView Earnings Details
11/2/2011($0.30)($0.32)ViewN/AView Earnings Details
8/4/2011($0.26)($0.36)ViewN/AView Earnings Details
5/4/2011($0.20)($0.29)ViewN/AView Earnings Details
2/10/2011($0.21)($0.20)ViewN/AView Earnings Details
10/28/2010Q3 2010($0.17)($0.24)ViewN/AView Earnings Details
8/5/2010Q2 2010($0.24)($0.23)ViewN/AView Earnings Details
4/28/2010Q1 2010($0.16)($0.06)ViewN/AView Earnings Details
2/4/2010Q4 2009$0.08$0.35ViewN/AView Earnings Details
10/29/2009Q3 2009($0.22)($0.28)ViewN/AView Earnings Details
7/30/2009Q2 2009($0.25)($0.23)ViewN/AView Earnings Details
5/8/2009Q1 2009($0.28)($0.24)ViewN/AView Earnings Details
2/6/2009Q4 2008($0.22)$0.26ViewN/AView Earnings Details
10/31/2008Q3 2008($0.25)($0.24)ViewN/AView Earnings Details
8/7/2008Q2 2008($0.20)($0.33)ViewN/AView Earnings Details
5/8/2008Q1 2008($0.16)($0.34)ViewN/AView Earnings Details
3/4/2008Q4 2007($0.39)($0.06)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

BioCryst Pharmaceuticals (NASDAQ:BCRX) Earnings Estimates

Current Year EPS Consensus Estimate: $-0.7 EPS
Next Year EPS Consensus Estimate: $-0.72 EPS

Dividends

Dividend History for BioCryst Pharmaceuticals (NASDAQ:BCRX)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

BioCryst Pharmaceuticals (NASDAQ BCRX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 5.60%
Institutional Ownership Percentage: 86.79%
Insider Trades by Quarter for BioCryst Pharmaceuticals (NASDAQ:BCRX)
Institutional Ownership by Quarter for BioCryst Pharmaceuticals (NASDAQ:BCRX)

BioCryst Pharmaceuticals (NASDAQ BCRX) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/13/2017William P SheridanCMOSell64,310$4.72$303,543.20View SEC Filing  
9/18/2017Fred E CohenDirectorSell54,250$5.42$294,035.00173,660View SEC Filing  
3/20/2017Thomas R Staab IICFOSell3,250$9.20$29,900.00144,710View SEC Filing  
3/10/2017Thomas R Staab IIInsiderSell3,250$9.06$29,445.00120,563View SEC Filing  
3/8/2017Thomas R Staab IIInsiderSell6,500$8.43$54,795.00123,813View SEC Filing  
3/6/2017Thomas R Staab IIInsiderSell3,250$7.90$25,675.00120,563View SEC Filing  
12/19/2016Thomas R Staab IIInsiderSell3,250$7.45$24,212.50127,437View SEC Filing  
9/14/2016Alane P BarnesVPSell8,357$4.27$35,684.3979,377View SEC Filing  
8/25/2016Yarlagadda S BabuVPSell30,000$4.06$121,800.00111,428View SEC Filing  
8/16/2016Bros. Advisors Lp BakerMajor ShareholderSell4,046,590$5.00$20,232,950.00View SEC Filing  
8/12/2016Thomas R Staab IIInsiderSell5,864$5.18$30,375.52128,745View SEC Filing  
8/9/2016Thomas R Staab IIInsiderSell14,577$4.43$64,576.11130,051View SEC Filing  
1/28/2016Bros. Advisors Lp Bakermajor shareholderBuy88,345$6.95$613,997.7523,459View SEC Filing  
1/22/2016Bros. Advisors Lp Bakermajor shareholderBuy106,800$7.28$777,504.0023,459View SEC Filing  
1/20/2016Bros. Advisors Lp Bakermajor shareholderBuy52,695$6.87$362,014.6523,459View SEC Filing  
1/19/2016Bros. Advisors Lp Bakermajor shareholderBuy92,200$7.12$656,464.0023,459View SEC Filing  
1/15/2016Bros. Advisors Lp Bakermajor shareholderBuy200,000$7.46$1,492,000.0023,459View SEC Filing  
12/21/2015Thomas R Staab IICFOSell3,052$10.86$33,144.72136,592View SEC Filing  
12/17/2015Thomas R Staab IICFOSell3,000$10.49$31,470.00139,644View SEC Filing  
7/20/2015Thomas R Staab IICFOSell3,500$16.50$57,750.00View SEC Filing  
6/22/2015Thomas R Staab IICFOSell3,750$16.00$60,000.00View SEC Filing  
6/19/2015Alane P BarnesVPSell3,000$15.00$45,000.00View SEC Filing  
6/19/2015Jon P StonehouseCEOSell20,000$15.02$300,400.00View SEC Filing  
6/19/2015Thomas R Staab IICFOSell16,375$14.36$235,145.00View SEC Filing  
6/19/2015William P SheridanCMOSell70,389$15.05$1,059,354.45View SEC Filing  
6/5/2015Thomas R Staab IICFOSell6,000$12.75$76,500.00View SEC Filing  
5/18/2015Thomas R Staab IICFOSell3,000$11.00$33,000.00View SEC Filing  
3/19/2015Yarlagadda S BabuVPSell12,105$10.16$122,986.80View SEC Filing  
3/5/2015Yarlagadda S BabuVPSell37,400$10.59$396,066.00View SEC Filing  
3/4/2015Yarlagadda S BabuVPSell10,495$10.50$110,197.50View SEC Filing  
2/20/2015Nancy J HutsonDirectorBuy10,000$10.27$102,700.00View SEC Filing  
12/30/2014William P SheridanCMOSell128,399$12.36$1,587,011.64View SEC Filing  
12/29/2014Thomas R Staab IICFOSell9,500$12.56$119,320.00View SEC Filing  
12/29/2014William P SheridanCMOSell105,295$12.43$1,308,816.85View SEC Filing  
8/27/2014Thomas R Staab IICFOSell10,000$13.58$135,800.00View SEC Filing  
7/1/2014Thomas R Staab IICFOSell3,125$13.00$40,625.00View SEC Filing  
6/23/2014Thomas R Staab IICFOSell3,125$12.49$39,031.25View SEC Filing  
6/17/2014Thomas R Staab IICFOSell3,125$12.00$37,500.00View SEC Filing  
3/14/2014Thomas Staab IICFOSell3,125$11.24$35,125.00126,616View SEC Filing  
3/6/2014Kenneth Lee, Jr.DirectorSell12,665$12.69$160,718.8510,252View SEC Filing  
11/12/2013George AbercrombieDirectorBuy3,000$6.19$18,570.006,000View SEC Filing  
8/1/2013Felix BakerMajor ShareholderBuy1,136,364$4.40$5,000,001.60View SEC Filing  
3/5/2013George B AbercrombieDirectorBuy3,000$1.23$3,690.00View SEC Filing  
12/14/2012Peder JensenDirectorBuy20,000$1.51$30,200.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

BioCryst Pharmaceuticals (NASDAQ BCRX) News Headlines

Source:
DateHeadline
BioCryst Pharmaceuticals and Idera Pharmaceuticals to Present at Two Upcoming Healthcare Investor Conferences - GlobeNewswire (press release)BioCryst Pharmaceuticals and Idera Pharmaceuticals to Present at Two Upcoming Healthcare Investor Conferences - GlobeNewswire (press release)
globenewswire.com - February 20 at 8:16 AM
BioCryst Pharmaceuticals and Idera Pharmaceuticals to Present at Two Upcoming Healthcare Investor ConferencesBioCryst Pharmaceuticals and Idera Pharmaceuticals to Present at Two Upcoming Healthcare Investor Conferences
feeds.benzinga.com - February 19 at 2:31 PM
Contrasting Tobira Development (TBRA) & BioCryst Pharmaceuticals (BCRX)Contrasting Tobira Development (TBRA) & BioCryst Pharmaceuticals (BCRX)
www.americanbankingnews.com - February 19 at 1:20 PM
BioCryst Pharmaceuticals (BCRX) Scheduled to Post Quarterly Earnings on MondayBioCryst Pharmaceuticals (BCRX) Scheduled to Post Quarterly Earnings on Monday
www.americanbankingnews.com - February 19 at 4:10 AM
Great Point Partners, LLC Opposes The BioCryst Pharmaceutical Proposed Merger With Idera Pharmaceuticals, Inc. - PR Newswire (press release)Great Point Partners, LLC Opposes The BioCryst Pharmaceutical Proposed Merger With Idera Pharmaceuticals, Inc. - PR Newswire (press release)
www.prnewswire.com - February 17 at 8:13 AM
BioCryst Pharmaceuticals (BCRX) Rating Lowered to Strong Sell at ValuEngineBioCryst Pharmaceuticals (BCRX) Rating Lowered to Strong Sell at ValuEngine
www.americanbankingnews.com - February 14 at 11:42 PM
BioCryst Pharmaceuticals, Inc. (BCRX) Expected to Post Quarterly Sales of $6.63 MillionBioCryst Pharmaceuticals, Inc. (BCRX) Expected to Post Quarterly Sales of $6.63 Million
www.americanbankingnews.com - February 12 at 4:30 AM
BioCryst Pharmaceuticals (BCRX) Stock Rating Upgraded by BidaskClubBioCryst Pharmaceuticals (BCRX) Stock Rating Upgraded by BidaskClub
www.americanbankingnews.com - February 11 at 10:16 PM
BioCryst Pharmaceuticals, Inc. (BCRX) Given Consensus Recommendation of "Hold" by BrokeragesBioCryst Pharmaceuticals, Inc. (BCRX) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - January 30 at 1:32 PM
$5.77 Million in Sales Expected for BioCryst Pharmaceuticals, Inc. (BCRX) This Quarter$5.77 Million in Sales Expected for BioCryst Pharmaceuticals, Inc. (BCRX) This Quarter
www.americanbankingnews.com - January 26 at 2:32 AM
Why 2018 Will Be Better for Biotech Deals Than 2017Why 2018 Will Be Better for Biotech Deals Than 2017
www.thestreet.com - January 25 at 9:28 AM
BioCryst and Idera to merge into rare disease company - MarketWatchBioCryst and Idera to merge into rare disease company - MarketWatch
www.marketwatch.com - January 24 at 8:06 AM
BioCryst Pharmaceuticals (BCRX) and Idera Pharmaceuticals (IDRA) Announce Merger - StreetInsider.comBioCryst Pharmaceuticals (BCRX) and Idera Pharmaceuticals (IDRA) Announce Merger - StreetInsider.com
www.streetinsider.com - January 24 at 8:06 AM
SHAREHOLDER ALERT: Monteverde & Associates PC Launches An Investigation of the Board of Directors and Officers of BioCryst Pharmaceuticals, Inc. - BCRXSHAREHOLDER ALERT: Monteverde & Associates PC Launches An Investigation of the Board of Directors and Officers of BioCryst Pharmaceuticals, Inc. - BCRX
finance.yahoo.com - January 23 at 5:26 PM
BioCryst Pharma And Idera Pharma To MergeBioCryst Pharma And Idera Pharma To Merge
www.nasdaq.com - January 22 at 3:54 PM
Critical Analysis: Aptevo Therapeutics (APVO) versus BioCryst Pharmaceuticals (BCRX)Critical Analysis: Aptevo Therapeutics (APVO) versus BioCryst Pharmaceuticals (BCRX)
www.americanbankingnews.com - January 9 at 9:30 PM
-$0.15 EPS Expected for BioCryst Pharmaceuticals, Inc. (BCRX) This Quarter-$0.15 EPS Expected for BioCryst Pharmaceuticals, Inc. (BCRX) This Quarter
www.americanbankingnews.com - January 7 at 5:28 PM
Head-To-Head Analysis: BioCryst Pharmaceuticals (BCRX) & Its RivalsHead-To-Head Analysis: BioCryst Pharmaceuticals (BCRX) & Its Rivals
www.americanbankingnews.com - January 6 at 9:12 PM
Investors Purchase Large Volume of Call Options on BioCryst Pharmaceuticals (BCRX)Investors Purchase Large Volume of Call Options on BioCryst Pharmaceuticals (BCRX)
www.americanbankingnews.com - January 6 at 3:12 AM
BioCryst Pharma (BCRX) Announces the Advancing of Potential Treatment for Rare and Severely Debilitating Fibrodysplasia Ossificans ProgressivaBioCryst Pharma (BCRX) Announces the Advancing of Potential Treatment for Rare and Severely Debilitating Fibrodysplasia Ossificans Progressiva
www.streetinsider.com - January 5 at 3:24 PM
BioCryst Pharma (BCRX) Announces the Advancing of Potential Treatment for Rare and Severely Debilitating ... - StreetInsider.comBioCryst Pharma (BCRX) Announces the Advancing of Potential Treatment for Rare and Severely Debilitating ... - StreetInsider.com
www.streetinsider.com - January 5 at 7:47 AM
BioCryst Advancing Potential Treatment for Rare and Severely Debilitating Fibrodysplasia Ossificans ProgressivaBioCryst Advancing Potential Treatment for Rare and Severely Debilitating Fibrodysplasia Ossificans Progressiva
finance.yahoo.com - January 5 at 7:46 AM
BioCryst Pharmaceuticals (BCRX) & Its Peers Critical AnalysisBioCryst Pharmaceuticals (BCRX) & Its Peers Critical Analysis
www.americanbankingnews.com - January 3 at 12:30 PM
BioCryst to Present at the 36th Annual J.P. Morgan Healthcare ConferenceBioCryst to Present at the 36th Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - January 3 at 11:09 AM
Here's Why BioCryst Pharmaceuticals Gained as Much as 15.7% TodayHere's Why BioCryst Pharmaceuticals Gained as Much as 15.7% Today
finance.yahoo.com - January 2 at 3:26 PM
Financial Review: BioCryst Pharmaceuticals (BCRX) and Its RivalsFinancial Review: BioCryst Pharmaceuticals (BCRX) and Its Rivals
www.americanbankingnews.com - December 27 at 3:34 AM
ETFs with exposure to BioCryst Pharmaceuticals, Inc. : December 26, 2017ETFs with exposure to BioCryst Pharmaceuticals, Inc. : December 26, 2017
finance.yahoo.com - December 26 at 1:06 PM
Zacks: Brokerages Expect BioCryst Pharmaceuticals, Inc. (BCRX) Will Post Quarterly Sales of $5.77 MillionZacks: Brokerages Expect BioCryst Pharmaceuticals, Inc. (BCRX) Will Post Quarterly Sales of $5.77 Million
www.americanbankingnews.com - December 24 at 10:50 AM
 Brokerages Anticipate BioCryst Pharmaceuticals, Inc. (BCRX) to Announce -$0.15 EPS Brokerages Anticipate BioCryst Pharmaceuticals, Inc. (BCRX) to Announce -$0.15 EPS
www.americanbankingnews.com - December 22 at 10:10 AM
BioCryst Pharmaceuticals (BCRX) Now Covered by Analysts at BarclaysBioCryst Pharmaceuticals (BCRX) Now Covered by Analysts at Barclays
www.americanbankingnews.com - December 21 at 12:14 AM
Reviewing BioCryst Pharmaceuticals (BCRX) and The CompetitionReviewing BioCryst Pharmaceuticals (BCRX) and The Competition
www.americanbankingnews.com - December 20 at 7:10 PM
Head to Head Comparison: BioCryst Pharmaceuticals (BCRX) & Its CompetitorsHead to Head Comparison: BioCryst Pharmaceuticals (BCRX) & Its Competitors
www.americanbankingnews.com - December 20 at 3:10 PM
BioCryst Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : BCRX-US : December 11, 2017BioCryst Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : BCRX-US : December 11, 2017
finance.yahoo.com - December 11 at 3:21 PM
Head to Head Survey: BioCryst Pharmaceuticals (BCRX) and Its RivalsHead to Head Survey: BioCryst Pharmaceuticals (BCRX) and Its Rivals
www.americanbankingnews.com - December 10 at 1:38 PM
ETFs with exposure to BioCryst Pharmaceuticals, Inc. : December 7, 2017ETFs with exposure to BioCryst Pharmaceuticals, Inc. : December 7, 2017
finance.yahoo.com - December 7 at 3:24 PM
BioCryst Pharmaceuticals, Inc. (BCRX) Expected to Post Quarterly Sales of $5.77 MillionBioCryst Pharmaceuticals, Inc. (BCRX) Expected to Post Quarterly Sales of $5.77 Million
www.americanbankingnews.com - December 6 at 6:26 AM
BioCryst Pharmaceuticals, Inc. :BCRX-US: Earnings Analysis: Q3, 2017 By the Numbers : December 5, 2017BioCryst Pharmaceuticals, Inc. :BCRX-US: Earnings Analysis: Q3, 2017 By the Numbers : December 5, 2017
finance.yahoo.com - December 5 at 3:23 PM
BioCryst Pharmaceuticals, Inc. – Value Analysis (NASDAQ:BCRX) : December 4, 2017BioCryst Pharmaceuticals, Inc. – Value Analysis (NASDAQ:BCRX) : December 4, 2017
finance.yahoo.com - December 4 at 3:22 PM
BioCryst Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : BCRX-US : December 1, 2017BioCryst Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : BCRX-US : December 1, 2017
finance.yahoo.com - December 1 at 8:13 AM
BioCryst Pharmaceuticals (BCRX) Presents At Jefferies 2017 London Healthcare Conference - SlideshowBioCryst Pharmaceuticals (BCRX) Presents At Jefferies 2017 London Healthcare Conference - Slideshow
seekingalpha.com - November 17 at 4:06 PM
BioCryst Pharmaceuticals, Inc. (BCRX) Receives Average Rating of "Hold" from BrokeragesBioCryst Pharmaceuticals, Inc. (BCRX) Receives Average Rating of "Hold" from Brokerages
www.americanbankingnews.com - November 16 at 2:02 PM
William P. Sheridan Sells 64,310 Shares of BioCryst Pharmaceuticals, Inc. (BCRX) StockWilliam P. Sheridan Sells 64,310 Shares of BioCryst Pharmaceuticals, Inc. (BCRX) Stock
www.americanbankingnews.com - November 15 at 8:44 PM
Analysts Issue Forecasts for BioCryst Pharmaceuticals, Inc.s FY2017 Earnings (BCRX)Analysts Issue Forecasts for BioCryst Pharmaceuticals, Inc.'s FY2017 Earnings (BCRX)
www.americanbankingnews.com - November 10 at 8:34 AM
Edited Transcript of BCRX earnings conference call or presentation 7-Nov-17 4:00pm GMTEdited Transcript of BCRX earnings conference call or presentation 7-Nov-17 4:00pm GMT
finance.yahoo.com - November 8 at 12:01 AM
BioCryst Pharmaceuticals, Inc. (BCRX) CEO Jon Stonehouse Q3 2017 Results - Earnings Call TranscriptBioCryst Pharmaceuticals, Inc. (BCRX) CEO Jon Stonehouse Q3 2017 Results - Earnings Call Transcript
seekingalpha.com - November 7 at 6:59 PM
BioCryst Reports Third Quarter 2017 Financial ResultsBioCryst Reports Third Quarter 2017 Financial Results
finance.yahoo.com - November 7 at 6:59 PM
BioCryst reports 3Q lossBioCryst reports 3Q loss
finance.yahoo.com - November 7 at 6:59 PM
Does BioCryst Pharmaceuticals Inc’s (BCRX) Debt Level Pose A Serious Problem?Does BioCryst Pharmaceuticals Inc’s (BCRX) Debt Level Pose A Serious Problem?
finance.yahoo.com - November 7 at 6:59 PM
BioCryst Pharmaceuticals, Inc. (BCRX) Releases Quarterly  Earnings Results, Hits EstimatesBioCryst Pharmaceuticals, Inc. (BCRX) Releases Quarterly Earnings Results, Hits Estimates
www.americanbankingnews.com - November 7 at 11:15 AM
BioCryst Pharmaceuticals, Inc. (BCRX) Releases Quarterly  Earnings Results, Hits EstimatesBioCryst Pharmaceuticals, Inc. (BCRX) Releases Quarterly Earnings Results, Hits Estimates
www.americanbankingnews.com - November 7 at 11:15 AM

SEC Filings

BioCryst Pharmaceuticals (NASDAQ:BCRX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

BioCryst Pharmaceuticals (NASDAQ:BCRX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

BioCryst Pharmaceuticals (NASDAQ BCRX) Stock Chart for Tuesday, February, 20, 2018

Loading chart…

This page was last updated on 2/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.